A IBUB study published in the journal Neurotherapeutics has validated a new pharmacological target for Alzheimer’s disease. The results show the inhibition of the enzyme soluble epoxide hydrolase (sEH) in murine models with the disease reduces the neuroinflammatory process, improving the endogen response of the organism and reducing the neuronal damage and death that cause this type of dementia. These results confirm the role of this enzyme in the evolution of Alzheimer’s disease and pinpoint its inhibition as a potential strategic target for this disease and for others that feature neuroinflammation.
The new study is led by the lecturers of the Faculty of Pharmacy and Food Sciences Mercè Pallàs (Institute of Neurosciences), Santiago Vázquez (Institute of Biomedicine of the UB – IBUB) Carles Galdeano (IBUB), and Christian Griñán-Ferré (Institute of Neurosciences). Other participants are the experts of the Institute of Biomedical Research of Barcelona (IIBB) — from CSIC and IDIBAPS—, the Autonomous University of Barcelona, the University of Santiago de Compostela and the California Davis University.
Griñán-Ferré, C.; Codony S.; Pujol, E.; Yang, J.; Leiva, R.; Escolano, C.; Puigoriol-Illamola, D.; Companys-Alemany, J.; Corpas, R.; Sanfeliu, C.; Pérez, B.; Loza, M.I.; Brea, J.; Morisseau, C.; Hammock, B. D.; Vázquez, S.; Pallàs, M. And C. Galdeano “Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease”, Neurotherapeutics, June, 2020. Doi: https://doi.org/10.1007/s13311-020-00854-1